<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We describe the clinical features, therapies, and clinical course of pulmonary arterial <z:hpo ids='HP_0000822'>hypertension</z:hpo> (<z:chebi fb="11" ids="104011,31204,33848,53305">PAH</z:chebi>) in a group of Filipinos with <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue diseases</z:e> (CTDs) </plain></SENT>
<SENT sid="1" pm="."><plain>We retrospectively reviewed the records of patients diagnosed with <z:chebi fb="11" ids="104011,31204,33848,53305">PAH</z:chebi> by a two-dimensional echocardiogram as a tricuspid regurgitant jet of more than 25 mmHg </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients had underlying CTDs, defined by the American College of Rheumatology criteria, and were seen at the rheumatology clinics of the University of Santo Tomas Hospital and the St </plain></SENT>
<SENT sid="3" pm="."><plain>Luke's Medical Center, Philippines </plain></SENT>
<SENT sid="4" pm="."><plain>Of the 33 patients (32 women) included in the analysis, there were 14 patients with <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE), 12 with <z:hpo ids='HP_0100324'>scleroderma</z:hpo>, 5 with <z:e sem="disease" ids="C0026272" disease_type="Disease or Syndrome" abbrv="MCTD">mixed connective tissue disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCTD</z:e>), 1 with <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> (APS), and 1 with <z:e sem="disease" ids="C0011633" disease_type="Disease or Syndrome" abbrv="">dermatomyositis</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The average age at <z:chebi fb="11" ids="104011,31204,33848,53305">PAH</z:chebi> diagnosis was 38 +/- 14 years (mean +/- SD), and the mean duration of illness from CTD to <z:chebi fb="11" ids="104011,31204,33848,53305">PAH</z:chebi> diagnosis was 53 +/- 52 months </plain></SENT>
<SENT sid="6" pm="."><plain>Twelve patients had died at the time of this report, with a median duration of 15 months (range 1-57 months) from <z:chebi fb="11" ids="104011,31204,33848,53305">PAH</z:chebi> diagnosis to mortality: six of these had <z:hpo ids='HP_0100324'>scleroderma</z:hpo>, five with SLE, and one with APS </plain></SENT>
<SENT sid="7" pm="."><plain>The following therapies were used in this group of patients: low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi>, <z:chebi fb="8" ids="10033">warfarin</z:chebi>, <z:chebi fb="0" ids="38215">calcium-channel blockers</z:chebi>, aspirin, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="51450">bosentan</z:chebi>, iloprost, and sildenafil </plain></SENT>
<SENT sid="8" pm="."><plain>We have described the clinical profile of <z:chebi fb="11" ids="104011,31204,33848,53305">PAH</z:chebi> in a group of Filipino patients with CTDs, most commonly SLE </plain></SENT>
<SENT sid="9" pm="."><plain>Various forms of pharmacologic therapies were used among these patients </plain></SENT>
<SENT sid="10" pm="."><plain>Mortality remains high, particularly among those with underlying <z:hpo ids='HP_0100324'>scleroderma</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Early recognition and treatment are crucial in order to provide a better outcome for these patients </plain></SENT>
</text></document>